A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. METHODS: Nine patients were prescribed Neuropharmagen(Ⓡ) for selection of antidepressants for individual patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyung Ho, Bahk, Won-Myong, Lee, Soo-Jung, Serretti, Alessandro, Pae, Chi-Un
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851455/
https://www.ncbi.nlm.nih.gov/pubmed/33508800
http://dx.doi.org/10.9758/cpn.2021.19.1.160
_version_ 1783645632901152768
author Lee, Kyung Ho
Bahk, Won-Myong
Lee, Soo-Jung
Serretti, Alessandro
Pae, Chi-Un
author_facet Lee, Kyung Ho
Bahk, Won-Myong
Lee, Soo-Jung
Serretti, Alessandro
Pae, Chi-Un
author_sort Lee, Kyung Ho
collection PubMed
description OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. METHODS: Nine patients were prescribed Neuropharmagen(Ⓡ) for selection of antidepressants for individual patient and their clinical outcomes were followed. RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
format Online
Article
Text
id pubmed-7851455
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-78514552021-02-28 A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat Lee, Kyung Ho Bahk, Won-Myong Lee, Soo-Jung Serretti, Alessandro Pae, Chi-Un Clin Psychopharmacol Neurosci Brief Report OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. METHODS: Nine patients were prescribed Neuropharmagen(Ⓡ) for selection of antidepressants for individual patient and their clinical outcomes were followed. RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients. Korean College of Neuropsychopharmacology 2021-02-28 2021-02-28 /pmc/articles/PMC7851455/ /pubmed/33508800 http://dx.doi.org/10.9758/cpn.2021.19.1.160 Text en Copyright© 2021, Korean College of Neuropsychopharmacology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Lee, Kyung Ho
Bahk, Won-Myong
Lee, Soo-Jung
Serretti, Alessandro
Pae, Chi-Un
A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
title A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
title_full A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
title_fullStr A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
title_full_unstemmed A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
title_short A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
title_sort practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851455/
https://www.ncbi.nlm.nih.gov/pubmed/33508800
http://dx.doi.org/10.9758/cpn.2021.19.1.160
work_keys_str_mv AT leekyungho apracticalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT bahkwonmyong apracticalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT leesoojung apracticalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT serrettialessandro apracticalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT paechiun apracticalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT leekyungho practicalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT bahkwonmyong practicalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT leesoojung practicalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT serrettialessandro practicalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat
AT paechiun practicalutilityandbenefitofpharmacogeneticbasedantidepressanttreatmentstrategyformajordepressivedisorderpatientswithdifficulttotreat

Ejemplares similares